Human Molecular Genetics Advance Access originally published online on December 8, 2004
Human Molecular Genetics 2005 14(3):385-390; doi:10.1093/hmg/ddi034
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Human Molecular Genetics, Vol. 14, No. 3 © Oxford University Press 2005; all rights reserved
An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia
1Institute of Human Genetics, GSF National Research Center for Environment and Health, Ingolstädter Landstr. 1, 85764 Munich–Neuherberg, Germany, 2Department of Pediatrics, Innsbruck Medical University, Anichstr. 35, 6020 Innsbruck, Austria and 3Institute of Human Genetics, Klinikum rechts der Isar, Technical University, Ismaningerstr. 22, 81675 Munich, Germany
* To whom correspondence should be addressed. Tel: +49 8931873296; Fax: +49 8931873297; Email: timstrom{at}gsf.de
Received October 4, 2004; Revised November 19, 2004; Accepted November 26, 2004
Familial tumoral calcinosis (FTC) is an autosomal recessive disorder characterized by ectopic calcifications and elevated serum phosphate levels. Recently, mutations in the GALNT3 gene have been described to cause FTC. The FTC phenotype is regarded as the metabolic mirror image of hypophosphatemic conditions, where causal mutations are known in genes FGF23 or PHEX. We investigated an individual with FTC who was negative for GALNT3 mutations. Sequencing revealed a homozygous missense mutation in the FGF23 gene (p.S71G) at an amino acid position which is conserved from fish to man. Wild-type FGF23 is secreted as intact protein and processed N-terminal and C-terminal fragments. Expression of the mutated protein in HEK293 cells showed that only the C-terminal fragment is secreted, whereas the intact protein is retained in the Golgi complex. In addition, determination of circulating FGF23 in the affected individual showed a marked increase in the C-terminal fragment. These results suggest that the FGF23 function is decreased by absent or extremely reduced secretion of intact FGF23. We conclude that FGF23 mutations in hypophosphatemic rickets and FTC have opposite effects on phosphate homeostasis.
AY753222 and AY753223.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Ubaidus, M. Li, S. Sultana, P. H. L. de Freitas, K. Oda, T. Maeda, R. Takagi, and N. Amizuka FGF23 is mainly synthesized by osteocytes in the regularly distributed osteocytic lacunar canalicular system established after physiological bone remodeling J. Electron Microsc. (Tokyo), December 1, 2009; 58(6): 381 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bergwitz, S. Banerjee, H. Abu-Zahra, H. Kaji, A. Miyauchi, T. Sugimoto, and H. Juppner Defective O-Glycosylation due to a Novel Homozygous S129P Mutation Is Associated with Lack of Fibroblast Growth Factor 23 Secretion and Tumoral Calcinosis J. Clin. Endocrinol. Metab., November 1, 2009; 94(11): 4267 - 4274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Samadfam, C. Richard, L. Nguyen-Yamamoto, I. Bolivar, and D. Goltzman Bone Formation Regulates Circulating Concentrations of Fibroblast Growth Factor 23 Endocrinology, November 1, 2009; 150(11): 4835 - 4845. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nakatani, M. Ohnishi, and M. S. Razzaque Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model FASEB J, November 1, 2009; 23(11): 3702 - 3711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ichikawa, A. H. Sorenson, A. M. Austin, D. S. Mackenzie, T. A. Fritz, A. Moh, S. L. Hui, and M. J. Econs Ablation of the Galnt3 Gene Leads to Low-Circulating Intact Fibroblast Growth Factor 23 (Fgf23) Concentrations and Hyperphosphatemia Despite Increased Fgf23 Expression Endocrinology, June 1, 2009; 150(6): 2543 - 2550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Masi, A. Gozzini, A. Franchi, D. Campanacci, A. Amedei, A. Falchetti, F. Franceschelli, G. Marcucci, A. Tanini, R. Capanna, et al. A Novel Recessive Mutation of Fibroblast Growth Factor-23 in Tumoral Calcinosis J. Bone Joint Surg. Am., May 1, 2009; 91(5): 1190 - 1198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. D. Carmichael, J. A. Bynum, and E. B. Evans Familial Tumoral Calcinosis: A Forty-Year Follow-up on One Family J. Bone Joint Surg. Am., March 1, 2009; 91(3): 664 - 671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Razzaque FGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player? Am J Physiol Renal Physiol, March 1, 2009; 296(3): F470 - F476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Nakatani, B. Sarraj, M. Ohnishi, M. J. Densmore, T. Taguchi, R. Goetz, M. Mohammadi, B. Lanske, and M. S. Razzaque In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) -mediated regulation of systemic phosphate homeostasis FASEB J, February 1, 2009; 23(2): 433 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Razzaque Does FGF23 toxicity influence the outcome of chronic kidney disease? Nephrol. Dial. Transplant., January 1, 2009; 24(1): 4 - 7. [Full Text] [PDF]
|
|
|
|
 |
|
 X. Bai, Q. Dinghong, D. Miao, D. Goltzman, and A. C. Karaplis Klotho ablation converts the biochemical and skeletal alterations in FGF23 (R176Q) transgenic mice to a Klotho-deficient phenotype Am J Physiol Endocrinol Metab, January 1, 2009; 296(1): E79 - E88. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Garringer, M. Malekpour, F. Esteghamat, S. M. J. Mortazavi, S. I. Davis, E. G. Farrow, X. Yu, D. E. Arking, H. C. Dietz, and K. E. White Molecular genetic and biochemical analyses of FGF23 mutations in familial tumoral calcinosis Am J Physiol Endocrinol Metab, October 1, 2008; 295(4): E929 - E937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. M. Gutierrez, M. Mannstadt, T. Isakova, J. A. Rauh-Hain, H. Tamez, A. Shah, K. Smith, H. Lee, R. Thadhani, H. Juppner, et al. Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis N. Engl. J. Med., August 7, 2008; 359(6): 584 - 592. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Olauson, T. Krajisnik, C. Larsson, B. Lindberg, and T. E Larsson A novel missense mutation in GALNT3 causing hyperostosis-hyperphosphataemia syndrome. Eur. J. Endocrinol., June 1, 2008; 158(6): 929 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Marsell, E. Grundberg, T. Krajisnik, H. Mallmin, M. Karlsson, D. Mellstrom, E. Orwoll, C. Ohlsson, K. B Jonsson, O. Ljunggren, et al. Fibroblast growth factor-23 is associated with parathyroid hormone and renal function in a population-based cohort of elderly men Eur. J. Endocrinol., January 1, 2008; 158(1): 125 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-A. Westerberg, T. Linde, B. Wikstrom, O. Ljunggren, M. Stridsberg, and T. E. Larsson Regulation of fibroblast growth factor-23 in chronic kidney disease Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3202 - 3207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Krajisnik, P. Bjorklund, R. Marsell, O. Ljunggren, G. Akerstrom, K. B Jonsson, G. Westin, and T. E Larsson Fibroblast growth factor-23 regulates parathyroid hormone and 1{alpha}-hydroxylase expression in cultured bovine parathyroid cells J. Endocrinol., October 1, 2007; 195(1): 125 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S Razzaque and B. Lanske The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis J. Endocrinol., July 1, 2007; 194(1): 1 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Stubbs, S. Liu, W. Tang, J. Zhou, Y. Wang, X. Yao, and L. D. Quarles Role of Hyperphosphatemia and 1,25-Dihydroxyvitamin D in Vascular Calcification and Mortality in Fibroblastic Growth Factor 23 Null Mice J. Am. Soc. Nephrol., July 1, 2007; 18(7): 2116 - 2124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Liu and L. D. Quarles How Fibroblast Growth Factor 23 Works J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1637 - 1647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ichikawa, V. Guigonis, E. A. Imel, M. Courouble, S. Heissat, J. D. Henley, A. H. Sorenson, B. Petit, A. Lienhardt, and M. J. Econs Novel GALNT3 Mutations Causing Hyperostosis-Hyperphosphatemia Syndrome Result in Low Intact Fibroblast Growth Factor 23 Concentrations J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1943 - 1947. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Sitara, M. S. Razzaque, R. St-Arnaud, W. Huang, T. Taguchi, R. G. Erben, and B. Lanske Genetic Ablation of Vitamin D Activation Pathway Reverses Biochemical and Skeletal Anomalies in Fgf-23-Null Animals Am. J. Pathol., December 1, 2006; 169(6): 2161 - 2170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ichikawa, E. A. Imel, A. H. Sorenson, R. Severe, P. Knudson, G. J. Harris, J. L. Shaker, and M. J. Econs Tumoral Calcinosis Presenting with Eyelid Calcifications due to Novel Missense Mutations in the Glycosyl Transferase Domain of the GALNT3 Gene J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4472 - 4475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Garringer, C. Fisher, T. E. Larsson, S. I. Davis, D. L. Koller, M. J. Cullen, M. S. Draman, N. Conlon, A. Jain, N. S. Fedarko, et al. The Role of Mutant UDP-N-Acetyl-{alpha}-D-Galactosamine-Polypeptide N-Acetylgalactosaminyltransferase 3 in Regulating Serum Intact Fibroblast Growth Factor 23 and Matrix Extracellular Phosphoglycoprotein in Heritable Tumoral Calcinosis J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 4037 - 4042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Strewler Disordered Secretion of FGF23 Links Three Disorders of Phosphate Transport IBMS BoneKEy, August 1, 2006; 3(8): 14 - 17. [Full Text] [PDF]
|
|
|
|
|
|
D. M. Antoniucci, T. Yamashita, and A. A. Portale Dietary Phosphorus Regulates Serum Fibroblast Growth Factor-23 Concentrations in Healthy Men J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 3144 - 3149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kato, C. Jeanneau, M. A. Tarp, A. Benet-Pages, B. Lorenz-Depiereux, E. P. Bennett, U. Mandel, T. M. Strom, and H. Clausen Polypeptide GalNAc-transferase T3 and Familial Tumoral Calcinosis: SECRETION OF FIBROBLAST GROWTH FACTOR 23 REQUIRES O-GLYCOSYLATION J. Biol. Chem., July 7, 2006; 281(27): 18370 - 18377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zhang, O. A. Ibrahimi, S. K. Olsen, H. Umemori, M. Mohammadi, and D. M. Ornitz Receptor Specificity of the Fibroblast Growth Factor Family: THE COMPLETE MAMMALIAN FGF FAMILY J. Biol. Chem., June 9, 2006; 281(23): 15694 - 15700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. White, T. E. Larsson, and M. J. Econs The Roles of Specific Genes Implicated as Circulating Factors Involved in Normal and Disordered Phosphate Homeostasis: Frizzled Related Protein-4, Matrix Extracellular Phosphoglycoprotein, and Fibroblast Growth Factor 23 Endocr. Rev., May 1, 2006; 27(3): 221 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Liu, W. Tang, J. Zhou, J. R. Stubbs, Q. Luo, M. Pi, and L. D. Quarles Fibroblast Growth Factor 23 Is a Counter-Regulatory Phosphaturic Hormone for Vitamin D J. Am. Soc. Nephrol., May 1, 2006; 17(5): 1305 - 1315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Olsen and F. S. Chew Tumoral calcinosis: pearls, polemics, and alternative possibilities. RadioGraphics, May 1, 2006; 26(3): 871 - 885. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M F Campagnoli, A Pucci, E Garelli, A Carando, C Defilippi, R Lala, G Ingrosso, I Dianzani, M Forni, and U Ramenghi Familial tumoral calcinosis and testicular microlithiasis associated with a new mutation of GALNT3 in a white family. J. Clin. Pathol., April 1, 2006; 59(4): 440 - 442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-i. Nabeshima Toward a better understanding of klotho. Sci. Aging Knowl. Environ., March 22, 2006; 2006(8): pe11 - pe11. [Abstract] [Full Text]
|
|
|
|
|
|
X. Yu, O. A. Ibrahimi, R. Goetz, F. Zhang, S. I. Davis, H. J. Garringer, R. J. Linhardt, D. M. Ornitz, M. Mohammadi, and K. E. White Analysis of the Biochemical Mechanisms for the Endocrine Actions of Fibroblast Growth Factor-23 Endocrinology, November 1, 2005; 146(11): 4647 - 4656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Razzaque, R. St-Arnaud, T. Taguchi, and B. Lanske FGF-23, vitamin D and calcification: the unholy triad Nephrol. Dial. Transplant., October 1, 2005; 20(10): 2032 - 2035. [Full Text] [PDF]
|
|
|
|
|
|
K. Araya, S. Fukumoto, R. Backenroth, Y. Takeuchi, K. Nakayama, N. Ito, N. Yoshii, Y. Yamazaki, T. Yamashita, J. Silver, et al. A Novel Mutation in Fibroblast Growth Factor 23 Gene as a Cause of Tumoral Calcinosis J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5523 - 5527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Larsson, S. I. Davis, H. J. Garringer, S. D. Mooney, M. S. Draman, M. J. Cullen, and K. E. White Fibroblast Growth Factor-23 Mutants Causing Familial Tumoral Calcinosis Are Differentially Processed Endocrinology, September 1, 2005; 146(9): 3883 - 3891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Imel and M. J. Econs Fibroblast Growth Factor 23: Roles in Health and Disease J. Am. Soc. Nephrol., September 1, 2005; 16(9): 2565 - 2575. [Full Text] [PDF]
|
|
|
|
|
|
T. Berndt and R. Kumar The Phosphatonins and the Regulation of Phosphorus Homeostasis IBMS BoneKEy, June 1, 2005; 2(6): 5 - 16. [Full Text] [PDF]
|
|
|
|
|
|
S. M. J. de Beur Tumoral Calcinosis: A Look into the Metabolic Mirror of Phosphate Homeostasis J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2469 - 2471. [Full Text] [PDF]
|
|
|
|
|
|
E. Seeman and G. J. Strewler Clinical and Basic Research Papers - January 2005 Selections IBMS BoneKEy, February 1, 2005; 2(2): 1 - 6. [Full Text] [PDF]
|
|